Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET
Company Participants
Anna Marie Wagner - SVP of Corporate Development
Jason Kelly - Co-Founder & CEO
Mark Dmytruk - CFO
Conference Call Participants
Matt Sykes - Goldman Sachs
Tejas Savant - Morgan Stanley
Rahul Sarugaser - Raymond James
Mark Massaro - BTIG
Steve Mah - Cowen
Derik De Bruin - Bank of America
Anna Marie Wagner
Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks again for joining us, and we look forward to providing you with an updating on our last quarter.
As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties. We'll follow our standard agenda for these calls, by an update on our financial progress, We followers , during our quarterly earnings calls, we will, of course, be updating you on our financial progress, while also taking an opportunity to dive deeper into an area of strategic importance as folks continue to develop a deeper understanding of what we're building.
As I said before their topics you'd like to see in a future deep dive, just look us now we love to include business in the future. As usual we'll end with a Q&A session and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance including, right now, via Twitter, #GinkgoResults or via e-mail at investors@ginkgobioworks.com.
And now, I'll hand it over to Jason to kick things off.
Jason Kelly
Thanks, Anna Marie. As a reminder Ginkgo's mission is to make biology easier to engineer, right. And this sort of focus on the tools and technology is embedded biology’s really what led to the platform business model that we're really pushing here at Ginkgo. And the way that works as a customer, brings ideas to Ginkgo, for a cell that they want to engineered to do something and we use our platform to engineer to program that cell for them to meet their specifications, right.
And the reason customers want to work with us, there are two core assets in that platform. The first is, our Foundry, right. So this is a highly automated lab and sort of key value proposition for our customers is, we can take what is typically an underutilized fixed cost investment i.e. their internal R&D labs at their site and turn that into a highly efficient variable cost for them if they instead engage with Ginkgo’s Foundry as a service provider of that sort of lab activity.